https://www.avient.com/sites/default/files/2021-12/Chemically Resistant Materials Whitepaper.pdf
M.; Edwards, J.
M.
M.
https://www.avient.com/sites/default/files/2022-03/Asia SEM Healthcare Product Selection Guide %281%29.pdf
PP OVERMOLDING HARDNESS REGULATORY STERILIZATION CHARACTERISTICS Dynaflex™ G2706 28A USP Class VI, ISO 10993, Food contact EtO Soft translucent grade, grippy feel Dynaflex™ G2711 43A USP Class VI, ISO 10993, Food contact EtO Highly colorable solution, grippy feel, low compression set Versaflex™ CL2242 & CL2250 42A/ 50A USP Class VI, ISO 10993, US Food contact EtO Clear boilable grades; ABS, PC bondable Versaflex™ G2705 N 60A USP Class VI, ISO 10993, Food contact EtO/Steam High resilience, low compression set Versaflex™ HC3810 20A-90A USP Class VI, ISO 10993 EtO General purpose, unfilled ABS, PC OVERMOLDING HARDNESS REGULATORY STERILIZATION CHARACTERISTICS Versaflex™ OM1040 40A USP Class VI, ISO 10993 EtO Translucent Versaflex™ OM3060 60A USP Class VI, ISO 10993 EtO Clear VERSAFLEX™ CL AND DYNAFLEX™ TPEs OVERMOLDING FOR ERGONOMICS • Adds good tactile surface with soft-touch feel • Available in a variety of color effects and textures • Improves grip, cushion, and comfort • Enhances functional performance like sealing properties, vibration damping, oxygen barrier, and scratch and abrasion resistance • Reduces assembly costs, good processability • Offers excellent adhesion to a wide range of substrates Applications: • Glucometers • Medical tools overmolds • Injector pens • Analysis devices VERSALLOY™ HC & VERSAFLEX™ HC TPEs SEALING & RESEALING • Rubbery feel and soft touch • No coring, good puncture, and resealability in static stoppers • Meets low coefficient of friction requirements in dynamic seals • Low extractables • Suitable to overmold onto polyolefins Applications: • Sealing and resealing septum • Seals and sanitary gaskets • Syringe plungers and tips MATERIAL DESCRIPTION HARDNESS REGULATORY STERILIZATION CHARACTERISTICS Versalloy™ HC 9210-45N 45A USP Class VI EtO Good processability, smooth surface aesthetics Versalloy™ HC 9210-55N 55A USP Class VI EtO Good processability, smooth surface aesthetics Versalloy™ HC 9210-70N 70A USP Class VI EtO Good processability, smooth surface aesthetics Versalloy™ HC 9220-43N 43A USP Class VI, ISO 10993-4/5 EtO Extrusion grade, high temperature resistance Versaflex™ HC 2110-35N 34A FDA, USP Class VI, ISO 10993 Autoclave EtO radiation Resealing, elevated comp set Versaflex™ HC 2110-57B 57A FDA, USP Class VI, ISO 10993 Autoclave EtO radiation Low stiction VERSAFLEX™ CL AND DYNAFLEX™ TPEs HIGH CLARITY GRADES WITHOUT PLASTICIZERS • Water clear grades formulated without phthalate plasticizers • Meets medical regulatory USP Class VI and ISO 10993-4,5 • Food contact and FDA compliant • Autoclave and radiation stable • Low extractable • High clarity (Haze 50 4.1, 100 4.5, 100 4, 70 6, 70 Tensile Modulus (MPa) 2200 2700 2600 2350 1820 1820 Flexural Strength (MPa) 80 90 104 86 68 68 Flexural Modulus (MPa) 2500 2700 2500 2300 1980 1590 HDT: 0.45, 1.8 (MPa) 110, 80 90, 80 100, 89 123, 100 123, 64 100, 70 UL-94 Rating @ 3.0 mm 5VA V-0 5VA V-0 HB V-0 UL-94 Rating @ 1.5 mm V-0 V-0 5VB V-0 HB V-0 UL-94 Rating @ 0.75 mm V-1 V-2 V-0 None None V-2 COMPETITIVE MATERIAL COMPARISON ENGINEERED POLYMER FORMULATIONS FOR HEALTHCARE TRILLIANT™ HC THERMOPLASTICS The family of Trilliant™ HC high-performance thermoplastics is formulated to meet the growing challenges of medical devices and equipment.
MATERIAL DESCRIPTION BASE RESIN Trilliant™ HC2020 Copolyester Trilliant™ HC8910/8920 Polyketone/ABS blend Trilliant™ HC2120 Tritan Trilliant™ HC3120 PC Trilliant™ HC5210 PP Trilliant™ HC6010 PA6 Trilliant™ HC6610 PA66 Trilliant™ GRV-NP-110-W PA12 TRILLIANT™ HC THERMOPLASTICS • Chemically resistant replacement for FR PC/ABS, FR PC/PET & FR COPE, providing UL 94 Yellow Card V-0 flame rating at 1.5 mm, V-1 at 0.75 mm thicknesses for a broad color spectrum • Outperforms PC/ABS, PC/PET and COPE in resistance to common disinfectants • Retains tensile strength after 72-hour exposure to common hospital disinfectants, and shows better long-term chemical resistance as compared to PC blends and COPE • Exhibits good impact and temperature resistance • Available in natural grades, standard medical colors, or custom pre-colored products Applications: • Medical device housings • MRI, X-ray, CT scanner components • Surgical instruments such as staplers, dissectors, scissors • Auto-injector pen TRILLIANT™ HC ELECTRICALLY CONDUCTIVE FORMULATIONS • Consistent conductivity ensures repeatable part performance and minimizes failures related to inconsistent electrical conductivity • High flow and easy processing facilitate filling of thin wall parts and multiple cavity tools, which enable faster cycle times and lower per-unit part costs • Superior durability reduces breakage and resultant scrap related costs • Less tendency to flash results in improved appearance and less fluid retention in or on the tip, thus driving greater accuracy and less potential for cross-contamination • High strength produces parts with greater stiffness and warp resistance, again minimizing scrap-related costs Applications: • Conductive pipette tips TEST TEMS SPECIFIC GRAVITY MELT FLOW RATE (230OC, 2.16KG) TENSILE STRENGTH FLEXURAL STRENGTH FLEXURAL MODULUS IMPACT STRENGTH NOTCHED, IZOD SURFACE RESISTIVITY Method ASTM D-792 ASTM D-1238 ASTM D-638 ASTM D-790 ASTM D-790 ASTM D-256 ASTM D-257 Unit -- g/10min MPa MPa MPa J/m Ohms/sq.
https://www.avient.com/sites/default/files/2025-02/Avient Investor Presentation - February 2025_w_Non-GAAP.pdf
All Rights Reserved 2025 4 Key Messages Avient is evolving to its next phase as an innovator of materials solutions to help our customers succeed, while enabling a sustainable world Our primary focus is on organic revenue growth and margin expansion ► intersect secular trends and high growth markets with our technologies ► build businesses in high growthcatalyze growth in our core markets ► hybridization Our strategy is enabled and driven by our focus on (a) portfolio prioritization, (b) amplifying innovation, (c) digital for operational excellence and growth, and (d) leadership, talent and culture for the Avient of the future Copyright © .
All Rights Reserved 2025 12 Disciplined capital allocation PRIORITIZATION AND PHILOSHOPY Capex Expected annual spend between 3-5% of revenue to support investment in organic growth M&A De-emphasized in near term; complement organic growth strategy with M&A over time, as needed 1 2 Dividends Increasing each year with underlying earnings growth 3 Debt pay down Target net debt to adjusted EBITDA less than 2.5x 4 Share repurchases Opportunistic buy backs 5 Copyright © .
All Rights Reserved 2025 Avient 2024 sales BUSINESS SEGMENTS END MARKETS REGIONS 63% 37% S E M C AI 23% 20% 15% 10% 10% 8% 7% 4% 3% Packaging Telecom Energy Defense Healthcare Building & construction Transportation Industrial Consumer 41% 35% 18% 6% US & Canada Latin America Asia Europe, Middle East and Africa 24Copyright © .
https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
Global Compact & fulfilled Communication of Progress (COP) requirements • New Sustainability Strategy overview page including our 2022 AIP ESG metrics • New ESG Performance page with ESG ratings, awards, and certifications • Increased disclosures on carbon emissions, including disclosure of Climate Change Scenario Analysis • Added new Product Stewardship and Chemical Management policies • Enhanced data reporting for Workforce Demographics • Improved social disclosures on human rights, dependent care and special leave and strategic training management 2021 SUSTAINABILITY REPORT Launching integrated sustainability website in parallel with report Aligned with leading reporting frameworks 9 ESG PERFORMANCE & AWARDS 10 84th ENVIRONMENTAL SOCIAL GOVERNANCE 2 1 3 (as of 6/30/22) 2022 O U TLO O K $429 $490 2021 2022E $3.05 $3.50 2021 2022E FY 2022 GUIDANCE (TOTAL COMPANY: CURRENT PORTFOLIO) 12 Sales Adjusted Operating Income $4,819 $5,100 2021 2022E + 6% Adjusted EPS + 14% + 15% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 20% excluding FX) 13 CASH FLOW / LEVERAGE ($ millions) 2022E Cash Flow from Operating Activities 400$ Less: Run-Rate CapEx (90) CapEx for Clariant Integration (10) CapEx for IT System Upgrade (15) Total CapEx (115) Free Cash Flow 285$ Adjusted EBITDA 635$ Net Debt / Adjusted EBITDA 1.6x 14 DYNEEMA / DISTRIBUTION UPDATES • Strong performance so far in 2022 in-line with our modeling • Acquisition to be finalized as early as September 1, pending standard regulatory process and closing conditions • Encouraging interest thus far from potential buyers for world-class business with a strong track record • Second round bids due in August DISTRIBUTION 15 PRO FORMA MODELING UPDATE 2022E ($M) Revenue 5,100$ 415$ 5,515$ (1,635)$ 3,880$ Adjusted EBITDA 635 130 765 (109) 656 EBITDA % 12% 31% 14% 7% 17% Adj.
EPS (ex Amort) 3.96$ 0.13$ 4.09$ (0.58)$ 3.51$ Pro Forma Leverage (12/31/2022E) Net Debt / Adjusted EBITDA 1.6x 3.4x 2.8x Forecast Dyneema Forecast + Dyneema Sale of Distribution Pro Forma 2022 TWO-YEAR LEVERAGE MODEL 16 3.5x 2.7x 1.6x 2.8x 2.4x 2.0x 2019PF 2020PF 2022E 2022PF 2023E 2024E Dyneema® AcquisitionClariant Color Acquisition (1) Pro forma for the acquisition of the Clariant Color business (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan (1) (1) (2) OUR SPECIALTY JOURNEY CONTINUES 17 • Dyneema® brings leading technology and brand with the World’s Strongest Fiber™, deep history of application development and strong management team focused on specialty applications • Dyneema® transaction is aligned with our previously stated acquisition goal of expanding our composites and fiber capabilities • Similar to our other technology expansion acquisitions, Dyneema® allows us to leverage our invest-to-grow strategy • The possible sale of our Distribution business also presents potential benefits with respect to leverage and EBITDA margins 7% 46% 66% 86% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2021 2022 PF % o f A dj u st ed E B IT D A (1 ) JVs Distribution Performance Products & Solutions Specialty (1) Adjusted EBITDA is EBITDA excluding corporate costs and special items (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution (2) Healthcare 4% Packaging 8% Consumer 10% Building & Construction 43% Industrial 15% Transportation 14% Energy 4% Telecom. 2% 2006 2022 Pro forma Healthcare 8% Packaging 23% Consumer 21% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% Defense 6% END MARKET TRANSFORMATION TO LESS CYCLICAL INDUSTRIES ( W IT H DY N E E MA, E X .
Annual Purchases RAW MATERIAL AND SUPPLY CHAIN UPDATE Based on 2021 purchases, excludes Distribution business SEGMENT DATA U.S. & Canada 50% EMEA 25% Asia 16% Latin America 9% 2021 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 19% Industrial 16% Building and Construction 10% Telecommunications 4% Energy 2% END MARKET REVENUE (1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs $2,402M $409M $919M $164M $1,631M $94M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $581M$4,819M (1) Transportation 11% Healthcare 15% 24 Packaging 34% Consumer 21% Healthcare 8% Industrial 16% Building & Construction 10% Transportation 9% Energy 1% Telecommunications 1% C O L O R , A D D I T I V E S & I N K S 2021 REVENUE | $2 .4 BILL ION US & Canada 32% EMEA 40% Asia 21% Latin America 7% END MARKET REGION 25 All charts reflect 2021 financials S P E C I A LT Y E N G I N E E R E D M AT E R I A L S Consumer 27% Healthcare 10% Packaging 7% Telecommunications 16% Transportation 11% Industrial 11% Building & Construction 11% Energy 7% 2021 REVENUE | $919 MILLION END MARKET US & Canada 55% EMEA 25% Asia 20% REGION 26 All charts reflect 2021 financials D I S T R I BU T I O N Healthcare 26% Consumer 23% Packaging 5% Industrial 20% Transportation 16% Building and Construction 8% Energy 1% Telecommunications 1% US & Canada 80% Asia 3% Latin America 17% END MARKET REGION K E Y S U P P L I ER S 2021 REVENUE | $1 .6 B ILL ION 27 All charts reflect 2021 financials TOTA L C O M PA N Y R E G I O N A L S A L E S BY END MARKET Packaging 30% Consumer 26%Healthcare 13% Industrial 14% Building & Construction 5% Telecommunications 2% Energy 2% Asia (16% of sales) Transportation 8% Packaging 32% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 12% Telecommunications 5% Energy 4% EMEA (25% of sales) Transportation 12% 28 Consumer 25% Healthcare 19% Packaging 10% Industrial 17% Building & Construction 10% Telecommunications 4% Energy 2% US & Canada (50% of sales) Transportation 13% Packaging 38% Consumer 33% Healthcare 8% Industrial 10% Building & Construction 5% Telecommunications 1% LATAM (9% of sales) Transportation 5% All charts reflect 2021 financials Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2024-08/Avient 2023 Sustainability Report_6.pdf
Montrose, Colorado Shanghai, China (b) 5.
Lima, Peru Suwanee, Georgia(b) 16.
Sandra B.
https://www.avient.com/sites/default/files/2024-08/Avient-2023-Sustainability-Report_5.pdf
Montrose, Colorado Shanghai, China (b) 5.
Lima, Peru Suwanee, Georgia(b) 16.
Sandra B.
https://www.avient.com/sites/default/files/resources/PolyOne%2520IR%2520Presentation%2520Sidoti%2520wNonGAAP%2520Rec.pdf
The non‐GAAP financial measures i l d dj t d EPS i b f i t t t d i ti dinclude: adjusted EPS, earnings before interest, tax, depreciation and amortization (EBITDA), adjusted EBITDA, net debt, Specialty platform operating income, Specialty platform gross margin percentage, adjusted operating income, return on invested capital, net debt/ EBITDA, and the exclusion of corporate p p charges in certain calculations.
Page 3 Strategy and Execution Drive Results 90% $22 $24 PolyOne Stock Price 50% 70% $18 $20 $22 S&P 500 (relative performance) 30% $12 $14 $16 S&P 500 (relative performance) ‐10% 10% $6 $8 $10 50% ‐30% $0 $2 $4 $ | ‐50%$0 2006 2007 2008 2009 2010 2011 2012 2013 Page 4 Four Pillar Strategy The World’s Premier Provider of SpecializedThe World s Premier Provider of Specialized Polymer Materials, Services & Solutions Page 5 Spartech – Compelling Strategic Rationale • Spartech expands PolyOne’s specialty portfolio with adjacent technologies in attractive end markets Bolt on acquisition with opportunity for global expansion as only Bolt‐on acquisition with opportunity for global expansion, as only 6% of Spartech’s revenues are outside of North America • PolyOne has a proven management team with a track record of transformational success • Preliminary synergy estimated at $65 million run rate by end of 3year 3 Significant opportunity to expand profitability by leveraging PolyOne’s four pillar strategy • Substantial potential share price appreciation for all shareholders f f ll / $ Accretive to EPS in first full year post‐acquisition / $0.50 once synergies realized Page 6 Mix Shift Highlights Specialty Transformation Old PolyOne Transformation 100% 2015 Target 80% In co m e* 65 – 75%40% 60% f O pe ra tin g 34% 43% 45% 65 75% 20% % o f 2%0% 2005 2008 2010 2012 2015 Specialty OI $5M $46M $87M $114M Target *Operating Income excludes corporate charges and special items JV's PP&S Distribution Specialty Page 7 Proof of Performance 2007 2012 2015 “Where we were” “Where we are” “Where we Where we were Where we are expect to be" 1) Operating Income % Specialty 3.2% 9.1% 12 – 16% PP&S 6.1% 9.0% 9 – 12% Distribution 3.0% 6.4% 6 – 7.5% 2) Specialty Platform sss% of Operating Income 20% 45% 65 – 75% 3) ROIC* ( ft t ) 7% 11% 15%3) ROIC* (after‐tax) 7% 11% 15% 4) Adjusted EPS Growth** N/A 4 yr CAGR = 55% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period **4 yr EPS CAGR calculated using 2012 adjusted EPS vs 2008 adjusted EPS Page 8 Proof of Performance Spartech Opportunity Intermediate PolyOne Spartech Opportunity 2006 2012 Today Goal “Where we were” “Where we are” “Where Spartech is”* “Where we can go”were are Spartech is can go Specialty Operating Margin 1.5% 9.1% 2.2% 8.0% – 10.0% Margin Page 9 *Pro Forma results include Spartech corporate allocations for FY12 ended November 3, 2012 At a Glance PolyOne Europe 14% Canada 8% Asia 5% Latin America 3% Distribution 2012 Revenues: $4.2 Billion* 2012 Revenues: $4.2 Billion* United States 70% 14% 5% PP&S 20%Specialty 57% 23% 70% Appliance 5% Building & HealthCare Transportation 16% Textiles 2% 1.02 1.20 $1.20 $1.40 ha re End Markets* EPS Growth g Construction 14% Wire & Cable 8% Consumer 8% Packaging 17% Industrial 11% Misc. 6% 9% 0.27 0 21 0.79 $0.40 $0.60 $0.80 $1.00 Ad ju st ed E ar ni ng s P er S Electrical & Electronics 4% 0.12 0.21 0.13 $0.00 $0.20 2006 2007 2008 2009 2010 2011 2012 Page 10 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms At a Glance Specialty U it d 2012 Revenues: $2.4 Billion* Solutions United States 59% Europe 23% Asia Canada 4% Asia 9% Latin America 5% Appliance 4% Building & C t ti HealthCare 5% Transportation 16% Textiles 2% % o f S al es 12-16% End Markets* Expanding Profits Construction 11% Wire & Cable 7% Electrical & Electronics Packaging 23% Industrial 7% Misc. 15% 1.5% 3.2% 4.3% 5.3% 8.4% 9.1% O pe ra tin g In co m e % 8.0% Electronics 4% Consumer 6% Page 11 2006 2007 2008 2009 2010 2011 2012 2015 O Target* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms At a Glance Designed Structures and Solutions United States 2012 Revenues: $0.85 Billion* Solutions 84% Europe 2% Canada 7% Latin America 7% Appliance 4% Building & Construction 11% Wire & Cable Sign & Advertising 3% Recreation & Leisure 2% Pool & Spa 1% Distribution & Thermoform 8% Textiles 2% Operating Income % of Sales 2012 Revenue by Industry Segment* Expanding Profits** Wire & Cable 7% Electrical & Electronics 4% Consumer 6% Packaging 23%Industrial 7% Transportation 16% 3% 2.2% 8 ‐ 10% 7% Misc. 1% HealthCare 5% 2012 2015 Target Page 12 *Pro Forma includes FY2012 results for Spartech (11/03/12 YE) **Pro Forma results include Spartech corporate allocations for FY12 Positioned for Earnings Growth 2015 Target Rev: $5B Adj.
EPS: $2.50 Assumptions • High single digit organic revenue CAGR • Operating margins in mid range of 2015 targets • No global recession• No global recession • No investment in incremental PP&S capacity • Completion of 2‐3 midsize accretive acquisitions • No divestitures • Housing starts at 85% of 50 year norm by 2015 R i f t bl b l 3X N t 2012 $ • Remain comfortably below 3X Net Debt / EBITDA Page 13 Rev: $3.0B Adj.
https://www.avient.com/resources/safety-data-sheets?page=2098
BARK NATURAL "B"
https://www.avient.com/resources/safety-data-sheets?page=5005
PE BEIGE B-10700
https://www.avient.com/resources/safety-data-sheets?page=685
B-15 BLUE PIGMENT